Experimental 'Triple-Target' drug tested for stubborn autoimmune illnesses
NCT ID NCT06888960
Summary
This early study is testing the safety of a new drug called CC312 in adults with severe autoimmune diseases that have not improved with standard treatments. The drug works by engaging the body's own immune T cells to attack harmful B cells, using a mechanism similar to some advanced cell therapies. Researchers will carefully monitor a small group of participants for side effects while finding the right dose, starting with very low amounts to minimize risks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, China, 300030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.